This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Chris H. Polman, MD
Department of Neurology

Hans E. van der Wiel, MD; Jacobus C. Netelenbos, MD, PhD
Department of Endocrinology

G. Jaap J. Teule, MD, PhD
Department of Nuclear Medicine

Johan C. Koetsier, MD, PhD
Department of Neurology Free University Hospital PO Box 7057 1007 MB Amsterdam, the Netherlands

Arch Neurol. 1991;48(10):1011-1012.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—A number of studies have shown that pulsed therapy with high-dose intravenously administered methylprednisolone is usually effective during multiple sclerosis (MS) relapses. It has been hypothesized that a regimen of repeated pulses of intravenous methylprednisolone, not restricted to relapses but given at regular intervals during the years of disease activity, might be effective in preventing progression of the disease. It can, however, reliably be predicted that under these circumstances the frequency of adverse effects will rise and, therefore, the importance of assessing the exact benefits and risks of such a regimen has been stressed in a number of leading articles.^1-3 We recently performed a small, open, pilot study in which monthly pulses of methylprednisolone (500 mg intravenously) were given to patients with progressive MS. Ten patients with definite MS according to the Poser criteria were selected for the study. During the 12 months before entry into . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?